IRVINE, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that updated clinical data from its ongoing open-label Phase 1b study evaluating tegoprubart for the prevention of rejection in subjects undergoing kidney transplantation will be presented at the World Transplant Congress (WTC) taking place in San Francisco from August 2-6, 2025. The oral presentation will feature updated results from approximately 30 kidney transplant recipients and will ...

17 July 2025 The Manager ASX Market Announcements Australian Securities Exchange Exchange Centre Level 4 20 Bridge Street Sydney NSW 2000 Electronic Lodgement Mirrabooka Investments Limited Full-Year Results Presentation Please find attached the presentation to be given at the Shareholder Webcast being held today, Thursday 17 July 2025 at 3.30pm (AEST). Webcast To join the webcast please use the following link: Webcast Link (This link will open directly in your internet browser). The shareholder presentatio ...

Can’t watch the Base presentation bc family time so someone give me a Tl;dw?The future of France or nah? ...

LIMA, Peru, July 15, 2025 /PRNewswire/ -- Intercorp Financial Services Inc. ("IFS" or "the Company") (BVL/NYSE: IFS) announced today that it will host its Second Quarter 2025 earnings conference call & video webcast presentation.The conference call will take place on Tuesday, August 12, 2025, at 10:00 a.m. E.T. / 9 a.m. Lima Time.Presenting for IFS:Mr. Luis Felipe Castellanos, Chief Executive Officer, Intercorp Financial ServicesMs. Michela Casassa, Chief Financial Officer, Intercorp Financial ServicesMr. C ...

Company Overview - Nilörn Group is a global company established in the 1970s, specializing in adding value to brands through branding and design, particularly in labels, packaging, and accessories for the fashion and clothing industry [1] - The company provides comprehensive, creative, and customized solutions in branding, design, product development, and logistics [1] - Nilörn Group operates through its own subsidiaries in multiple countries, including Sweden, Denmark, the UK, Germany, Belgium, Portugal, Hong Kong, India, Turkey, China, Bangladesh, Italy, Switzerland, Vietnam, the USA, and Pakistan [1] Upcoming Presentation - A presentation will be held via Teams on July 16 at 08:30 am CET, where the CEO will present the report [2] - Participants can register for the presentation through a provided link [2]

Core Insights - Neurocrine Biosciences presented new data from the Phase 3 CAHtalyst studies showing that CRENESSITY® (crinecerfont) leads to significant improvements in weight-related outcomes for patients with classic congenital adrenal hyperplasia (CAH) [1][2][5] Group 1: Study Overview - The Phase 3 CAHtalyst program is the largest interventional clinical trial for classic CAH, involving 285 patients (103 pediatric and 182 adult) [2][12] - The studies included a double-blind, placebo-controlled period followed by an open-label period where all patients received CRENESSITY [2][12] Group 2: Weight-Related Outcomes - Adult patients treated with CRENESSITY showed a mean BMI reduction of 0.8 kg/m² compared to a 0.4 kg/m² reduction in the placebo group at Month 12 [4][6] - 39% of adult patients on CRENESSITY achieved over a 5% weight reduction, compared to 14% in the placebo group [4][6] - Pediatric patients on CRENESSITY maintained reductions in BMI standard deviation scores (SDS) through Week 52, while those on placebo saw an increase [6][4] Group 3: Insulin Resistance Improvements - Significant reductions in insulin resistance were observed in both adult and pediatric patients treated with CRENESSITY compared to placebo [5][6] - The mean HOMA-IR score decreased more significantly in the CRENESSITY group than in the placebo group [6][7] Group 4: Safety Profile - CRENESSITY demonstrated a favorable safety profile, with common side effects being mild to moderate and not leading to discontinuation of the drug [8][20] - Common side effects in children included headache and stomach pain, while adults reported fatigue and headache [8][22] Group 5: Regulatory and Market Context - Data from the CAHtalyst studies supported the FDA approval of CRENESSITY in December 2024 [15] - CRENESSITY is positioned to evolve the standard of care for classic CAH by allowing for reduced glucocorticoid doses while maintaining or improving androgen control [2][16]

HOUSTON, July 11, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O’Heeron, will present at the Advanced Wound Care Summit USA in Boston, Massachusetts, on July 15, 2025. The presentation will includ ...

HOUSTON, July 10, 2025 (GLOBE NEWSWIRE) -- Targa Resources Corp. (NYSE: TRGP) ("Targa" or the "Company") announced today that its board of directors has declared a quarterly cash dividend of $1.00 per common share, or $4.00 per common share on an annualized basis, for the second quarter of 2025. This cash dividend will be paid August 15, 2025 on all outstanding common shares to holders of record as of the close of business on July 31, 2025. The Company will report its second quarter 2025 financial results b ...

Core Insights - Cytokinetics is set to present five key studies related to aficamten at the European Society of Cardiology Congress 2025, highlighting its potential in treating obstructive hypertrophic cardiomyopathy (HCM) [1][4] - The MAPLE-HCM trial compares aficamten with metoprolol, focusing on exercise capacity in patients with left ventricular outflow tract (LVOT) obstruction [2][4] - A late-breaking presentation will address the incidence and impact of atrial fibrillation across three clinical trials involving aficamten [1][2] Presentation Details - The MAPLE-HCM presentation will be led by Dr. Pablo Garcia-Pavia on August 30, 2025, at 9:18 AM CEST in Madrid [2] - The late-breaking clinical science presentation on atrial fibrillation will be conducted by Dr. Ahmad Masri on August 31, 2025, at 4:45 PM CEST in Budapest [2] - Another presentation on the long-term efficacy and safety of aficamten will be given by Dr. Sara Saberi on August 31, 2025, at 5:40 PM CEST [2] Additional Research - A poster presentation will analyze the effect of aficamten compared to metoprolol on cardiac structure and function in symptomatic obstructive HCM [3] - An integrated safety analysis of aficamten in patients with obstructive HCM will also be presented [3] Company Overview - Cytokinetics is a biopharmaceutical company specializing in cardiovascular diseases, with over 25 years of experience in muscle biology [4] - The company is preparing for potential regulatory approvals and commercialization of aficamten following positive results from the SEQUOIA-HCM trial [4] - Cytokinetics is also developing other drug candidates targeting heart failure and muscular dystrophy [4]

Core Insights - Plus Therapeutics, Inc. is focused on developing targeted radiotherapeutics for central nervous system (CNS) cancers, with a particular emphasis on leptomeningeal metastases (LM) and recurrent glioblastoma (GBM) [5] - The company's subsidiary, CNSide Diagnostics, will present its CNSide Cerebrospinal Fluid (CSF) Assay Platform at the SNO/ASCO CNS Metastases Conference, showcasing its clinical utility in managing patients at risk for CNS metastases [1][2] Company Overview - Plus Therapeutics is a clinical-stage pharmaceutical company headquartered in Houston, Texas, developing advanced platform technologies for CNS cancers [5] - CNSide Diagnostics specializes in proprietary laboratory-developed tests to identify tumor cells that have metastasized to the CNS, enhancing patient management for those with leptomeningeal metastases [3] Industry Context - Leptomeningeal metastases occur in approximately 5% of patients with metastatic cancer, with breast cancer, lung cancer, and melanoma being the most common sources [4] - Median survival for patients with LM is typically between 2 to 6 months, indicating a significant need for novel therapeutic options [4]